Physician profile
Arthur Chin
NPI 1659462299
$6,754.37
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,224 · 2020: $1,281 · 2021: $1,249.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $1,369.23 | 2019 | |
| Amarin Pharma, INC. | $824.74 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $511.47 | 2019-2021 | |
| Amgen INC. | $502.39 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $477.13 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $425.44 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $392.15 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.60 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $249.10 | 2019-2021 | |
| Pfizer INC. | $232.19 | 2019-2020 | |
| Esperion Therapeutics, INC. | $213.48 | 2021 | |
| Chiesi USA, INC. | $125.67 | 2019 | |
| Dynavax Technologies Corporation | $124.99 | 2019 | |
| Shire North American Group INC | $121.01 | 2019 | |
| Sanofi-Aventis U.S. LLC | $113.95 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $110.76 | 2019 | |
| Gilead Sciences, INC. | $109.58 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.70 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $99.17 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $85.44 | 2021 | |
| Abiomed | $82.43 | 2021 | |
| Lundbeck LLC | $70.64 | 2020-2021 | |
| Abbott Laboratories | $44.21 | 2019-2021 | |
| Boston Scientific Corporation | $21.70 | 2019 | |
| Siemens Medical Solutions USA, INC. | $16.20 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.